all things to do with diabetes obesity and metabolism
24th November 2022, Dr Chee L Khoo
One of the problems in primary care in trying to keep up to date is that 1) there is just so many guidelines we need to keep track of 2) we don’t when the new guidelines are updated. It is often mentioned that, on average, it takes 16 years when guidelines are published before it lands on our desk and be adopted in practice.…
21st November 2022, Dr Chee L Khoo
Have you noticed that we don’t use the term “CCF” anymore. The heart doesn’t have to be congested (as in fluid overloaded) to be in failure. We think about how the heart is not performing to its best to pump blood to all parts of the body that requires bloods. We call that heart failure because the heart has “failed” to pump blood adequately to tissues requiring blood.…
14th November 2022, Dr Chee L Khoo
We all have patients with high triglycerides (TG) that warrant intensification of our lipid lowering treatment. Statins are efficacious in reducing total cholesterol (TC), increasing high density lipoprotein cholesterol (HDL-C) and reducing low density lipoprotein cholesterol (LDL-C). Statins also reduce triglycerides levels but often these patients have residual hypertriglyceridaemia that warrants the addition of a fibrate to get our TG to target.…
13th November 2022, Dr Chee L Khoo
Gestational diabetes mellitus (GDM) is one many factors that changes future generations. Maternal overnutrition, and excessive gestational weight gain with or without GDM lead to foetal overgrowth, and “programs” the offspring with an increased risk of obesity and type 2 diabetes mellitus (T2D) in childhood and adulthood. The aetiology of obesity and T2D is multifactorial and involves complex interactions between genetic, environmental and behavioural factors.…
28th October 2022, Dr Chee L Khoo
Point-of-Care Testing (POCT) is defined as laboratory testing conducted close to the site of patient care, typically by clinical personnel whose primary training is not in the clinical laboratory sciences, or by patients (self-testing). In theory, POCT which produce results within minutes can assist in management of a number of chronic diseases. It could be useful in patients whose adherence to appointments is often an issue or in patients who are time poor and would prefer to attend the practice as infrequently as possible.…
23rd October 2022, Dr Chee L Khoo
The UKPDS 33 demonstrated that intensive glucose control had significant microvascular benefits over a 10-year period in patients with newly (< 6 years) diagnosed type 2 diabetes (1). Overall, there was a trend towards macrovascular benefits during that period but did not reach statistical significance. The participants were followed up for another 10 years after the study was published in 1997.…
13th October 2022, Dr Chee L Khoo
Obesity, type 2 diabetes mellitus (T2D), fatty liver disease, and cardiovascular disease (CVD) are complex and very inter-related cardio-metabolic conditions. Most of these conditions have lipids derangements as a major contributor to complications. While the link between lipids, in particular LDL-C, and CVD is linear and robust, there is still residual risks after aggressive treatment with lipid lowering agents.…
13th October 2022, Dr Chee L Khoo
Patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) are not only more likely to progress towards renal failure requiring dialysis or renal transplant, but also have a greater lifetime risk of cardiovascular (CV) morbidity and mortality (1). This is not surprising though, as both the kidneys and the heart share the same pathophysiology.…
25th September 2022, Dr Chee L Khoo
We looked at the Australian guidelines on management of heart failure (HF) recently and in particular, how it impacts upon the management of these patients in primary care. The guidelines recommended the four pillars of management but also reinforced the categories of HF. Did you know that the numbers that define the different categories of HF is somewhat arbitrary?…
14th September 2022, Dr Chee L Khoo
Diabetic retinopathy (DR) will affect up to 1 in 3 of our patients with diabetes. It is a sad statistic but it’s even more scary in women. In fact, DR is the leading cause of irreversible blindness in women of reproductive age. Much of the risk can be minimised or prevented in primary care.…
9th September 2022, Dr Chee L Khoo
While aspirin does provide a modest benefit in reducing nonfatal MI and nonfatal stroke events, low dose aspirin has little or no effect on cardiovascular disease mortality or all-cause mortality in patients who have not had cardiovascular disease (1). In 2016, the US Preventive Services Task Force (USPSTF) concluded that the beneficial effect of aspirin for the primary prevention of CVD was modest and occurred at doses of 100 mg or less per day (2).…
29th August 2022, Dr Chee L Khoo
By now, you would be very familiar with the additional cardiorenal benefits when you use an SGLT2 inhibitor (SGLT2i) in the management of hyperglycaemia in patients with type 2 diabetes (T2D). You would also know that the benefits are enjoyed by patients whether they have diabetes or not. DAPA-CKD published in September 2020 during the pandemic.…